Overview
The combination of CJC-1295 and Ipamorelin brings together two peptides that stimulate growth hormone (GH) release through different mechanisms. CJC-1295 is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) that increases GH release by targeting GHRH receptors. Ipamorelin is a selective agonist of the ghrelin (growth hormone secretagogue) receptor. Used together, they elevate GH via distinct pathways to promote a balanced release pattern that supports lean muscle development, metabolism, sleep quality, and recovery.
The combination of CJC-1295 and Ipamorelin brings together two peptides that stimulate growth hormone (GH) release through different mechanisms. CJC-1295 is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) that increases GH release by targeting GHRH receptors. Ipamorelin is a selective agonist of the ghrelin (growth hormone secretagogue) receptor. Used together, they elevate GH via distinct pathways to promote a balanced release pattern that supports lean muscle development, metabolism, sleep quality, and recovery.
Key Benefits of CJC-1295 and Ipamorelin
- Enhances Muscle Growth and Repair: Stimulates GH to support lean mass and tissue recovery.
- Promotes Fat Loss: Increases fat metabolism by elevating GH and IGF-1.
- Supports Bone Health: May improve bone mineral density and reduce fracture risk.
- Improves Sleep Quality: Encourages deeper, more restorative sleep via GH modulation.
- Cardiovascular Support: May strengthen overall cardiovascular function.
How It Works
- CJC-1295: Binds GHRH receptors in the pituitary to trigger GH release while preserving the body’s natural pulsatile rhythm.
- Ipamorelin: Mimics ghrelin to stimulate GH release and lessen somatostatin inhibition.
Together they create a sustained GH profile with healthy peaks and troughs, supporting muscle, bone, and metabolic benefits.
Clinical Applications
- Muscle and Bone Health: Increases muscle mass, supports bone density, and aids tissue repair.
- Metabolic Health: Assists fat loss and may help with insulin resistance management.
- Healthy Aging: Supports endogenous GH output, which naturally declines with age.
- Recovery and Rehabilitation: Aids post-surgical healing and general recovery through higher GH availability.
Research and Evidence (Highlights)
- CJC-1295 and GH Release: Reports show 2–10× increases in plasma GH with preserved pulsatility, supporting bone density, protein synthesis, and muscle growth.
- Ipamorelin and Bone Health: In animal models, counters glucocorticoid-induced bone loss and increases bone mineral density.
- Ipamorelin and Muscle: Reduces nitrogen loss and mitigates muscle wasting in glucocorticoid settings.
- CJC-1295 and Fertility: Early studies suggest potential roles in ovulation and possible relevance to male fertility via GH/IGF-1 pathways.
Side Effects and Safety
Generally well-tolerated. Possible mild, transient effects include injection site pain, nausea, flushing, dizziness, drowsiness, headache, or flu-like symptoms. Most effects resolve spontaneously.
Generally well-tolerated. Possible mild, transient effects include injection site pain, nausea, flushing, dizziness, drowsiness, headache, or flu-like symptoms. Most effects resolve spontaneously.
Product Information
- Product Name: CJC-1295 and Ipamorelin
- Supplied As: Injectable solution or nasal spray
- Suggested Usage: For individuals seeking enhanced GH stimulation, metabolic support, improved sleep, and recovery benefits.
Applications
- Muscle and Bone Health
- Metabolic Function and Fat Loss
- Healthy Aging and Recovery
- Improved Sleep Quality
CJC-1295: Structure and Details
- Formula: C152H252N44O42
- Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg
- Molecular Weight: 3367.954 g/mol
- PubChem CID: 56841945
Mechanism Summary
CJC-1295 promotes pituitary GH secretion while maintaining physiologic pulsatility. Ipamorelin provides a fast, short-acting GH pulse via ghrelin receptor activation. The combination offers a steadier overall GH profile than either alone.
CJC-1295 promotes pituitary GH secretion while maintaining physiologic pulsatility. Ipamorelin provides a fast, short-acting GH pulse via ghrelin receptor activation. The combination offers a steadier overall GH profile than either alone.
Administration (General Guidance)
- Route: Subcutaneous injection to the abdominal area or other fatty tissue, or as directed when using nasal spray.
- Preparation: Use sterile technique. Clean the injection site with alcohol. Pinch the skin, insert at 90°, depress plunger fully, withdraw, and dispose safely.
- Timing: Doses are typically taken on an empty stomach, at least one hour away from food.
- Onset: CJC-1295 peaks in approximately 1–4 hours and persists for days; Ipamorelin acts quickly with a shorter half-life of about two hours.
Benefits Noted Over Time (Illustrative Timeline)
- Month 1: Higher energy, improved stamina, deeper sleep.
- Month 2: Healthier skin appearance, stronger nails and hair, faster metabolism.
- Month 3: Enhanced libido and focus, improved joint comfort.
- Months 4–6: Continued fat reduction, improved skin elasticity, increased lean mass and overall vitality.
Referenced Citations (Selected)
- Raun K., et al. Ipamorelin as a selective GH secretagogue. Eur J Endocrinol. 1998.
- Andersen N.B., et al. Ipamorelin counters glucocorticoid-induced bone effects. Growth Horm IGF Res. 2001.
- Svensson J., et al. GH secretagogues increase bone mineral content. J Endocrinol. 2000.
- Aagaard N.K., et al. GH and secretagogues on nitrogen balance. Growth Horm IGF Res. 2009.
- Adeghate E., Ponery A.S. Ipamorelin and insulin release. Neuro Endocrinol Lett. 2004.
- Beck D.E., et al. Ipamorelin in postoperative ileus. Int J Colorectal Dis. 2014.
- Fowkes M.M., et al. GHS derivatives for PET imaging. Eur J Med Chem. 2018.
- Ionescu M., Frohman L.A. Pulsatile GH during CJC-1295 stimulation. J Clin Endocrinol Metab. 2006.
- Alba M., et al. CJC-1295 normalizes growth in GHRH knockout mice. Am J Physiol Endocrinol Metab. 2006.
- Volpe A., et al. GRF for superovulation. Hum Reprod. 1991.
- Jetté L., et al. Identification of CJC-1295 as a long-lasting GRF analog. 2005.
